Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mercaptopurine Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | PI4KA | P42356 | 2/20 | 0.34 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.34 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.34 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9142303 | 0.88 | LMNA (0.38) | LMNAHTTCYP3A4HSD17B10ALOX15 | |
| Hypoxanthine SCHEMBL4367641 | 0.86 | LMNA (0.39) | LMNAHTTCYP3A4HSD17B10ALOX15 | |
| Adenine SCHEMBL593934 | 0.85 | PI4KA (0.54) | LMNAHTTCYP3A4HSD17B10ALOX15 | |
| SCHEMBL98133 | 0.85 | HSD17B10 (0.38) | LMNAHTTCYP3A4HSD17B10ALOX15 | |
| SCHEMBL9396874 | 0.83 | HTT (0.36) | LMNAHTTCYP3A4HSD17B10ALOX15 | |
| Dimethyladenine SCHEMBL1997329 | 0.82 | CDK2 (0.57) | LMNAHTTCYP3A4HSD17B10ALOX15 | |
| SCHEMBL4202116 | 0.82 | CYP3A4 (0.45) | LMNAHTTCYP3A4HSD17B10TSHR | |
| Ribose (Furanose) SCHEMBL7680729 | 0.81 | CYP3A4 (0.39) | LMNAHTTCYP3A4HSD17B10ALOX15 | |
| Ribose (Furanose) SCHEMBL831005 | 0.81 | CYP3A4 (0.39) | LMNAHTTCYP3A4HSD17B10ALOX15 | |
| Mercaptopurine Anhydrous SCHEMBL4451627 | 0.79 | LMNA (0.36) | LMNAHTTHSD17B10CHEK1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0036145-B1 | AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1985-05-29 | — | — | EP | claimed |
| EP-2516637-B1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | PLASMIA BIOTECH S L (ES) | 2016-04-20 | — | — | EP | disclosed |
| US-8759034-B2 | Thermostable biocatalyst combination for nucleoside synthesis | PLASMIA BIOTECH, S.L. (ES) | 2014-06-24 | — | — | US | disclosed |
| US-20130337547-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | BRILL ENGINES, S.L. (ES) | 2013-12-19 | — | — | US | disclosed |
| US-8512997-B2 | Thermostable biocatalyst combination for nucleoside synthesis | PLASMIA BIOTECH, S.L. (ES) | 2013-08-20 | — | — | US | disclosed |
| EP-2516637-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | Plasmia Biotech, S.L. (ES) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264175-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | BRILL ENGINES, S.L. (ES) | 2012-10-18 | — | — | US | disclosed |
| WO-2011076894-A1 | THERMOSTABLE BIOCATALYST COMBINATION FOR NUCLEOSIDE SYNTHESIS | INSTITUT UNIV. DE CIÈNCIA I TECNOLOGIA, S.A. (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338985-A1 | Thermostable biocatalyst combination for nucleoside synthesis | Institut Univ. de Ciència i Tecnologia, s.a. (ES) | 2011-06-29 | — | — | EP | disclosed |
| EP-0746294-B1 | ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS | ODONTEX INC (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2000026406-A1 | METHOD FOR INDEXING AND DETERMINING THE RELATIVE CONCENTRATION OF EXPRESSED MESSENGER RNAs | DIGITAL GENE TECHNOLOGIES, INC. (US) | 2000-05-11 | — | — | WO | disclosed |
| EP-0746294-A4 | ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS | ODONTEX INC (US) | 1998-04-22 | — | — | EP | disclosed |
| EP-0746294-A1 | ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS | ODONTEX, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995009590-A1 | ABSORPTION ENHANCERS FOR TOPICAL PHARMACEUTICAL FORMULATIONS | ODONTEX, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| US-5082866-A | Alkylester amine compound | ODONTEX, INC. (US) | 1992-01-21 | — | — | US | disclosed |
| US-4980378-A | Increase penetration of drugs | ODONTEX, INC. (US) | 1990-12-25 | — | — | US | disclosed |
| US-4845233-A | TOPICAL PENETRATION ENHANCER FOR PHYSIOLOGICALLY ACTIVE AGENTS | IPRX, INC. (US) | 1989-07-04 | — | — | US | disclosed |
| EP-0036145-B1 | AN ORALLY ADMINISTERED DRUG FORM COMPRISING A POLAR BIOACTIVE AGENT AND AN ADJUVANT | INTERx RESEARCH CORPORATION (US) | 1985-05-29 | — | — | EP | disclosed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | disclosed |
| EP-0035770-A2 | An orally administered drug form comprising a glycosidic antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-16 | — | — | EP | disclosed |